Rezurock▼ (Belumosudil) is intended for HCPs practising in Great Britain (England, Scotland and Wales) only.

TRANSPLANT

<h3>Treatment of steroid refactory chronic GvHD</h3>

EBMT 2024: Treatment of steroid refractory chronic GvHD

Length: 15mins
In this video, Professor Mohty provides an overview of SR-chronic GvHD, highlighting poor outcomes and the high mortality rate in this population. Mohty also explores the current treatment options for the individuals that have SR-chronic GvHD through theoretical patient cases.

This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only.

Download ROCKstar study summary. This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only​.

Get in touch with the Transplant Team

Abbreviations

<h3>Frontline treatment of chronic GvHD</h3>

EBMT 2024: Frontline treatment of chronic GvHD

Length: 15mins
In this video, Dr Francesca Bonifazi discusses the current treatment paradigm for chronic GvHD. She explores frontline options and appropriate patient populations. Dr Bonifazi highlights the need for early intervention with cGvHD and how this may improve outcomes.

<h3>QoL and cGvHD</h3>

EBMT 2024: QoL and chronic GvHD

Length: 15mins
Dr Kinsella highlights the varied nature of chronic GvHD symptoms in this video. She talks about how they can have a notable impact on the daily lives of patients. It also explores the treatment burden associated with chronic GvHD management, highlighting that individuals often require frequent hospital visits as well as multiple treatments to control their condition. Dr Kinsella discusses the side effects of some chronic GvHD treatments, (e.g. steroids), and how this can have a noteable impact on the overall quality of life of patients.

<h3>Roundtable: Exploring clinical cases</h3>

EBMT 2024: Roundtable: Exploring clinical cases

Length: 15mins
Following the presentation of an example of clinical cases by the co-chairs, the faculty engaged in a dynamic discussion that ascertained how they would approach the management of this patient.

<h3>Pulmonary chronic GvHD: The need for early identification and improved management</h3>

EBMT 2024: Pulmonary chronic GvHD: The need for early identification and improved management

Length: 15mins
In this video, Saskia Bos describes how pulmonary complications and high mortality rates in chronic GvHD emphasise the need for early identification and better management. She addresses the challenges in the diagnosis, the limitations of the NIH criteria, the need for treatment guidelines, the role of novel therapeutics, and more randomised trials.

<h3>The late effects of chronic GvHD: The challenge of long term management</h3>

EBMT 2024: The late effects of chronic GvHD: The challenge of long-term management

Length: 10 mins
Michelle Kenyon talks about the long-term complications associated with chronic GvHD in this video, as well as how these complications may vary in severity and impact patient quality of life.

The InTen Nurse Forum is a series of promotional meetings for GB HCPs only organised and funded by Sanofi. This Forum provides knowledge in the management of chronic Graft Versus Host Disease (GVHD), as well as an opportunity to hear from your peers on best practices.

For nurses and allied healthcare professionals with an interest in chronic GvHD

InTen Nurse Forum - ACCEND Framework

Length: 09:00
In this video, Sara introduces the ACCEND (Aspirant Cancer Career and Education Development) programme for nurses and allied HCPs and its different components: Career pathway, core capabilities in practice and the educational framework.

Sara Main is a BMT and Cellular Therapy nurse at University Hospitals Southampton. Care of cancer patients has been the focus of almost all her nursing career. She is passionate about bone marrow transplant and committed to quality care for patients and families.
She is a committee member of EBMT UK NAP group and is dedicated to enhancing clinical, educational. and leadership skills to better support transplant and cellular therapy patient support at every step of their treatment pathway.
Sara emphasizes the critical role of quality in transplant and cell therapy nursing, advocating for patient safety and experience through education and governance activities.
Despite challenges, she believes in the profession's ability to lead change in treating these conditions and that it is an exciting time to be a BMT and Cellular Therapy nurse.

Vote for content for future events

There will be more InTen Nurse Forum events in the coming months and we want to hear from you.&nbsp; 
Let us know what topics you are interested in by clicking below and fill out the form. Your voice will shape our future events.

Help us to shape our future events

Download ROCKstar study summary. This is intended for HCPs practising in Great Britain (England, Scotland, Wales) only​

InTen Nurse Forum: What is chronic GvHD?

Length: 20:00
In this video you can learn from John the basics of chronic GvHD, how it impacts quality of life, its classification and measurement, and current treatment challenges.

John Murray is a nurse clinician in BMT at the Haematology and Transplant Unit of The Christie NHSFT where he first joined as the Transplant Coordinator and Apheresis nurse in 2001. Then he developed a new post of nurse clinician in BMT with a special interest in GvHD and late effects of transplant.
He has been Chair of the EBMT UK NAP group and also Chair of the EBMT scientific committee. He became President of EBMT NG in 2017, serving for 4 years and is currently a Past President. He gives regular presentations on issues related to transplantation with a special interest in GvHD. John is also Co-chair of the Equality Diversity and Inclusion committee of EBMT.

MenQuadfiTM▼ (Meningococcal (Group A,C,W,Y) Conjugate Vaccine)

OTHER-VACCINES-TOPICS

VACCINES

MenQuadfiTM&nbsp;is only available privately in Great Britain, but is available UK-wide as part of the UK National Immunisation Programme when ordered through ImmForm.

<h2 class="contentBlock__subtitle text-title-3 text- font-title block">Introduction</h2>
Sanofi is committed to Social Value and offering ways to address social and environmental issues through working practices.
One example of this is our MenQuadfi™ eco-pack. The benefits of which are outlined below.
As the end user, we need your help. The cardboard packaging can be recycled, rather than thrown out with the vial and needles. If you are able to separate the cardboard boxes and recycle them, you help us complete the loop of our eco-packaging and make an impact, one small action at a time.

<h2>Intelligent packaging design for single vaccines</h2>

*vs previous MenACWY tender provider. 
 +This is a calculation for the total carbon equivalent of 4.6 tonnes of plastic blister weight removed from the programme over a 4 year contract, using MenQuadfiTM instead of the previous provider.

<h2>Recycle Right posters for use at your school</h2>

Vaccines Eco-pack Recycling

To read this content, please activate your Sanofi Campus account via the email we've sent to you.

If you didn't receive our first email at {email} to confirm your account you can request a new one below. If you don't see it, you may need to check your spam folder.

title

In order to see relevant content, tell us what you are interested in

Title

Create new password

complete your profile to help us provide you with content that's relevant to you.

Your profile is incomplete

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

Enjoy more exclusive content{newline}by <a>registering today</a>

MAT-XU-2300297 (v3.0) - Date of preparation: October 2023

MAT-XU-2305062 (v1.0) - Date of preparation: November 2023

MAT-XU-2300297 (v3.0) Date of Preparation: October 2023

MAT-XU-2305047 (v1.0) - Date of preparation: November 2023

Already have an account? <a>Sign in here</a>

Best practices on optimising patient care

Get a customised view of the topics that you're interested in, along with the ability to save content to watch or read at a later date.

Unlimited access to premier content, white papers, case studies, research papers, webinars, training, and up-to-date scientific medical resources.

Personalised content based on your areas of interest

Connect and stay up-to-date with peers in your area of speciality and topics of interest through free events and leadership forums.

Please sign in to continue and read the full article

Please sign up to continue reading the full article.

We respect your privacy and will not share your information with any 3rd parties.

Topical guides written specifically for patients

Unlimited access to the latest patient guide guides and resources. Share content with your patients with easy-to-use online tools.

Please complete your profile to read the content.

Your profile is not validated yet. Please verify your inbox.

Restricted Access

We can't find the page you're looking for

You are going to a website that is not operated by Sanofi. Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party site to which you link.

You are about to leave Sanofi Campus website.

You are now leaving this site to visit a partner website.

Thank you for visiting COPD Sanofi Campus.

This website is for healthcare professionals only.

Welcome to COPD Sanofi Campus.

Welcome to COPD Sanofi Campus

Please refresh the page to access the content

Sorry, something went wrong

The page you are looking for may be under maintenance, or the link may be incorrect.

Sorry, we can't find this page

You are going to a website that is not operated by Sanofi or a Sanofi website where the terms of use may differ. For external websites, Sanofi has no control over the content or availability of linked sites or resources, and accepts no liability or responsibility for them or for any loss or damage that may arise from your use of them. Please ensure that you read the legal and privacy policy sections of any third-party or Sanofi sites.

You are now leaving the Sanofi campus UK website

You are about to leave Campus.sanofi/uk.

Thank you for registering. Before we get started, we need to confirm your email address to ensure that we have the correct information.

Please follow these steps to complete your registration:

Would you like to receive future text messages about Beyfortus updates?

Sanofi is here to help support your patients, their families, and caregivers. For more information regarding Beyfortus®, call <a.callPhoneNumberBeyfortus>1-855-BEYFORTUS (1-855-239-3678)</a.callPhoneNumberBeyfortus> or sign up below to receive the latest updates via email or text. All fields are required.

Would you like to learn more about Beyfortus® (nirsevimab-alip) 50 mg and 100 mg injection? Leave us your contact details, and a Sanofi representative will be in touch.

Do you want to participate in the Beyfortus Reservation Program?

What information are you interested in learning more about? (Optional)

Request a visit from your local ALPROLIX representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local ALTUVIIIO representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Request a visit from your local QFITLIA representative to learn more. Call <a.callPhoneNumberAltuviiio>1-800-745-4447</a.callPhoneNumberAltuviiio>, Option 5, or complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your ALPROLIX® Representative or receive updates about ALPROLIX. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

Sign up to schedule an office visit with your QFITLIA Representative or receive updates about QFITLIA. Please complete the form below. The information you provide will be maintained in accordance with our <a.usPrivacyPolicy>Privacy Policy</a.usPrivacyPolicy>. All fields are required.

This site is intended for UK healthcare professionals only and contains information on Sanofi UK's medicines, educational resources and more. Please click the appropriate button below. By entering this site, you are confirming that you are a UK healthcare professional. This site contains promotional information. Please note that some of the content on the website is only relevant for HCPs practising in Great Britain (England, Scotland, Wales). This website is optimised for desktop use, and some features may perform differently on mobile devices.

MAT-XU-2300297 (v6.0) - Date of Preparation: April 2024

Welcome to Sanofi Campus UK

This content is only available to registered users. Please sign in or register to view this content.

Please Sign In

Email verification

You're seeing a preview of the portal. Clear your cookies (by closing your browser window for example) to go back to public mode.

We've updated our privacy notice to better protect your data and enhance your experience. Please take a moment to review the changes by <privacyNewTab>clicking here</privacyNewTab>. Your privary matters for us. Please click on continue to confirm you have read the new privacy notice.

Privacy Notice Update

Communication consent

My Consent

{resultsCount, plural, one {result} other {results}}

Please sign in to access to the results

You need to sign-in to your account in order to access medical content.

To access the results, please register in under 1 minute

You are now leaving the Sanofi content section of our site and entering the external medical bibliographic search content section.

You are entering to the External Scientific Content Site

You are now leaving the external medical bibliographic search section of our site and entering the Sanofi content section.

Latest Education